Clinical Trial Agreement Checklist For Healthtech Startups

Priya runs a Manchester healthtech startup that has built an app to monitor patients after cardiac procedures. A private clinic is interested in running a 60-patient pilot, and a university researcher wants to help analyse the results.

It feels like a huge step forward until Priya receives a 28-page clinical study contract with clauses on protocol deviations, adverse events, publication rights, insurance, UK GDPR and ownership of trial data.

If you're in a similar position, you're not alone. A clinical trial agreement can look like a formal research document, but it has very real commercial consequences for your product, your data, your IP and your ability to raise investment later.

Let's break down the clauses your healthtech startup should check before signing.

What Is A Clinical Trial Agreement?

A clinical trial agreement is the contract that sets out who is responsible for what during a clinical trial, clinical services arrangement, clinical investigation, pilot study or research project.

In a UK healthtech context, you might see it called a:

• Clinical trial agreement, often used for trials involving medicinal products or regulated clinical research.
• Clinical study contract, a broader term often used for pilots, observational studies or evaluations.
• Research collaboration agreement, especially where a university, NHS organisation or research partner is contributing expertise, facilities or analysis.
• Clinical investigation agreement, commonly used for medical devices.

The wording matters because different laws and approval pathways may apply. For example, a trial of an investigational medicinal product will usually involve the Medicines for Human Use (Clinical Trials) Regulations 2004 and the Medicines and Healthcare products Regulatory Agency. A medical device study may involve the UK Medical Devices Regulations 2002 and MHRA guidance.

The agreement doesn't replace the protocol, ethics approval, participant information sheet or data protection documents. Instead, it sits around them and makes the commercial position clear.

For example, it should say who recruits participants, who obtains consent, who reports adverse events, who pays the clinic, who can publish the findings, who owns improvements to the technology and who carries the insurance if something goes wrong.

Do I Need A Clinical Trial Agreement Solicitor In The UK?

It depends on the study, but if you're dealing with patients, health data, a clinic, a university, an NHS body or a regulated medical product, you should get the agreement reviewed before you sign.

Many teams search for a clinical trial agreement solicitor because these contracts mix commercial, data protection, IP and regulatory issues. You don't just need someone to tidy the wording. You need the contract to match the trial protocol, your insurance cover, your privacy documents and your commercial plans for the product.

Legal review is especially useful where:

• Your startup will be named as the sponsor, co-sponsor or data controller.
• The study involves special category health data under the UK GDPR and the Data Protection Act 2018.
• A university or hospital wants publication rights over the results.
• The contract gives someone else ownership of inventions, algorithms, datasets or improvements.
• The clinic asks you to provide a broad indemnity for patient injury, protocol breaches or data issues.
• You're planning to use the study results in investor materials, regulatory submissions or marketing claims.

Templates can be a helpful starting point, especially where an NHS or university site has a standard form. But a template won't know whether your app is a medical device, whether your study is interventional, or whether your investor expects your company to own the trial outputs.

If cost is on your mind, the main drivers are usually the number of parties, whether the study is regulated, how complex the data flows are, and how heavily negotiated the IP and indemnity clauses are. A free template may be fast but risky, an online fixed-fee legal service can give more certainty, and a traditional firm billing by the hour may suit a larger or highly regulated project.

What Trial Responsibilities Should The Contract Spell Out?

The contract should spell out each party's responsibilities in enough detail that there's no confusion once recruitment starts.

This is where your healthtech clinical trial contract needs to line up with the protocol. If the protocol says the clinic will screen patients and perform follow-up calls, but the contract says your startup is responsible for all trial procedures, you may have a problem when something is missed.

At a minimum, check who is responsible for:

• Preparing and maintaining the protocol.
• Obtaining ethics approval, Health Research Authority approvals where relevant, and any MHRA approvals or notifications.
• Recruiting, screening and enrolling participants.
• Obtaining informed consent and providing participant information sheets.
• Training site staff on your software, device or platform, including any medical device distribution limits.
• Supplying devices, login access, equipment or study materials under a product supply arrangement.
• Keeping trial records, delegation logs and source data.
• Monitoring protocol compliance and managing deviations.
• Reporting adverse events, serious adverse events and product complaints.
• Managing audits, inspections and regulator queries.

Example: Adverse Event Reporting

Say Priya's startup agrees to run a 60-patient study across 3 clinics. The contract says each clinic must report any serious adverse event to Priya's company within 24 hours of becoming aware of it. Priya's company, as sponsor, is then responsible for assessing whether the event is related to the app and making any required regulatory reports.

That 24-hour site reporting deadline isn't just admin. It gives Priya's team time to decide whether a safety report must go to the MHRA, a Research Ethics Committee or another body.

For a trial of an investigational medicinal product, a fatal or life-threatening suspected unexpected serious adverse reaction is generally reportable as soon as possible and no later than 7 days, with follow-up information within a further 8 days. Other suspected unexpected serious adverse reactions are generally reportable no later than 15 days. The exact obligations depend on the study type, so the contract should point to the protocol, safety reporting plan and applicable rules.

How Should A Clinical Trial Agreement Deal With Data And Confidentiality?

It should clearly explain what data is being collected, who controls it, who can use it and how it will be protected.

Clinical studies usually involve health data, which is special category personal data under the UK GDPR. That means you need more than a simple confidentiality clause. Your contract should work alongside your privacy notice, participant consent materials, data protection impact assessment and any data processing agreement.

Start by working out each party's role. Depending on the study, your startup, the clinic, sponsor, university or CRO may be:

• An independent controller, making its own decisions about why and how personal data is used.
• A joint controller, sharing decisions about the purposes and means of processing.
• A processor, handling personal data on another party's instructions.

If a party is a processor, Article 28 of the UK GDPR requires specific processor terms. These cover things like security, sub-processors, breach assistance, deletion or return of data and audit rights.

Your agreement should also deal with:

• Whether participant data will be anonymised, pseudonymised or identifiable.
• Who can access raw data and who can access aggregated results.
• Where data will be hosted and whether it leaves the UK.
• How data subject requests will be handled.
• How quickly a party must notify the others of a data breach. Many contracts require notice within 24 or 48 hours so the controller can assess whether the Information Commissioner's Office must be notified within 72 hours.
• How long records will be kept after the study ends.

Confidentiality clauses should protect your commercial information too. That might include your source code, product roadmap, pricing, investor materials, unpublished results, algorithms, technical documents and know-how. Make sure confidentiality obligations survive termination, because data analysis and publications can happen long after recruitment ends.

Who Owns The IP And Results From A Clinical Study?

The contract should separate your existing IP from new IP created during the study, then say who owns each category and who can use it.

This is one of the biggest commercial points for healthtech startups. If the wording is too broad, you could accidentally give a clinic, university or sponsor rights over your platform, model, algorithm or future product improvements.

A good IP clause usually separates:

• Background IP, meaning what each party already owns before the study starts.
• Study results, such as datasets, reports, analysis, outcomes and conclusions from the research and development work.
• Arising IP, meaning inventions, improvements, software, methods or know-how created during the project.
• Licences, meaning limited rights to use someone else's IP for the study or for agreed future purposes.

For example, your startup might keep ownership of the app and algorithm, the clinic might keep ownership of its clinical procedures and patient records, and the parties might agree that your startup owns product improvements that relate to the platform. The university may receive a licence to use de-identified results for academic research and publication.

Publication rights need careful drafting. Universities and clinicians will often expect the right to publish legitimate scientific findings. That's normal, but you may need a review period before publication so you can remove confidential information or file a patent application first.

A common approach is to give your business 30 to 90 days to review a proposed publication. If a patent filing is needed, the agreement may allow a further delay. This matters because public disclosure can damage patent novelty before you file with the UK Intellectual Property Office or another patent office.

The contract should also say whether you can use the study outcomes in marketing, investor decks, grant applications and regulatory submissions. Don't assume you can quote results publicly just because you helped fund the study.

What Should Go Into A Clinical Trial Agreement Checklist?

Your checklist should cover the parties, trial operations, money, data, IP, publication rights, insurance and exit rights before anyone starts work.

Here is a practical outline you can use to review a clinical trial agreement UK document or brief your legal team. It's not a finished legal document, and a lawyer should tailor it to your study, product, protocol and regulatory pathway before you use it.

1. Parties And Roles: Name each clinic, university, sponsor, CRO, investigator and your startup, then define each party's role.
2. Study Description: Attach or identify the protocol, study title, sites, participant numbers, start date and expected duration.
3. Regulatory Approvals: State who obtains MHRA, ethics, HRA or other approvals and who maintains them.
4. Site Duties: List recruitment, consent, training, equipment use, protocol compliance, record keeping and reporting obligations.
5. Payments And Costs: Set out fees, pass-through costs, invoicing, VAT treatment and what happens if recruitment is slower than expected.
6. Safety Reporting: Define adverse events, serious adverse events, product complaints and reporting timeframes.
7. Data Protection: Identify controllers and processors, attach any data processing terms and describe security, retention and breach notice requirements.
8. Confidential Information: Protect technical, commercial, clinical and unpublished information, and say how long confidentiality lasts.
9. IP Ownership: Separate background IP, study results, arising IP, inventions, software, datasets and licences.
10. Publication Rights: Set review periods, confidentiality carve-outs, patent filing delays and rules for using names or logos.
11. Insurance And Indemnities: Confirm what cover each party must hold and what losses each party is responsible for.
12. Monitoring And Audit: Cover site access, inspection support, record retention and regulator requests.
13. Termination: Explain when the agreement can end, what happens to enrolled participants, unpaid fees, data and equipment.
14. Governing Law: State the law of the contract, usually England and Wales for many UK commercial arrangements.

Common Contract Traps To Check

Watch out for clauses that make your startup responsible for everything, even where the clinic controls the site or the investigator controls clinical decisions. Also be careful with indemnities that aren't linked to fault, breach, negligence or your product.

On the IP side, be wary of wording that gives the other party ownership of all results or all improvements, especially if those improvements relate to your core technology. On the data side, don't sign until the controller and processor roles are clear.

Key Takeaways

• A clinical trial agreement is a commercial contract, not just a research formality. It can affect your data, IP, insurance and product roadmap.
• Your contract should match the protocol, ethics documents, insurance policy and data protection documents.
• Adverse event reporting, protocol compliance and sponsor responsibilities need to be clear before recruitment begins.
• Health data needs careful UK GDPR and Data Protection Act 2018 wording, especially around controller roles, processors and breach notices.
• IP clauses should protect your background technology and clearly deal with study results, inventions, licences and publication rights.
• Templates can help you spot the issues, but clinical study contracts work best when they're tailored to your product, partners and regulatory pathway.

If you'd like help with reviewing or drafting your clinical trial agreement, your data protection terms, your IP clauses and your publication rights, you can reach us at 08081347754 or team@sprintlaw.co.uk for a free, no-obligations chat.